This inventor holds 4 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Wake Forest University. Active years: 2016-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2016-2022
Title: Andrew Karim Kader: Inventor in Genetic Risk Assessment
Introduction
Andrew Karim Kader is an inventor associated with Wake Forest University in San Diego, California. His work includes methods and compositions for assessing prostate cancer risk using genetic markers. He holds 4 patents.
Latest Patents
One of Kader’s latest listed inventions, “Methods and Compositions for Correlating Genetic Markers with Prostate Cancer Risk,” describes a way to estimate an individual’s risk of developing prostate cancer. The method analyzes a nucleic acid sample to determine genotypes at multiple biallelic polymorphic loci, then uses those results to calculate a cumulative relative risk (CRR).
According to the invention’s description, a CRR greater than 1.00 indicates increased risk. The assessment may also help identify individuals who could be candidates for early prostate-specific antigen (PSA) screening, prostate biopsy, or chemoprevention.
Career Highlights
Kader’s listed patent work focuses on applying genetic information to prostate cancer risk assessment. The described approach combines results from multiple genetic markers into a cumulative measure intended to support clinical decision-making.
Collaborations
Kader’s listed coworkers include Jianfeng Xu and Jielin Sun. His work is associated with Wake Forest University.
Conclusion
Andrew Karim Kader’s patent work highlights a genetic-marker-based approach to estimating prostate cancer risk and informing potential screening and prevention decisions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile